Extracorporeal Membrane Oxygenation (ECMO) Systems Market - Forecast(2022 - 2027)

Report Code: HCR 0561 Report Format: PDF + Excel

Extracorporeal Membrane Oxygenation (ECMO) Systems Market Overview

Extracorporeal Membrane Oxygenation (ECMO) Systems Market size is estimated to reach $391.8 million by 2026, growing at a CAGR of 5.3% during the forecast period 2021-2026. Extracorporeal membrane oxygenation (ECMO) is a progressive kind of life-backing technology whereby venous blood is oxygenated exterior to the body and restored to the patient. ECMO was originally utilized as last-resort rescue therapy for patients with serious respiratory failure. The increasing occurrences of cardiopulmonary ailment and respiratory failure are driving the growth of the Extracorporeal Membrane Oxygenation (ECMO) Systems Market. Extracorporeal Life Support (ECLS) or Extracorporeal Membrane Oxygenation (ECMO) includes the artificial backing of lung and/or heart operation utilizing an instrument that oxygenates a patient’s blood exterior to the body and restores it's utilizing a pump, thus permitting the heart and lungs to rest. Artificial ventilation (also termed artificial respiration) is a method of helping or exciting respiration, a metabolic process alluding to the complete swap of gases in the body by pulmonary ventilation, external respiration, and internal respiration. Studies have been conducted on written guidelines and knowledgeable assessments accessible on mechanical ventilation (a kind of artificial ventilation) particularly the management of patients needing Extracorporeal Membrane Oxygenation (ECMO). Cardiopulmonary bypass (CPB) is a method in which a machine briefly manages the operation of the heart and lungs at the time of surgery, keeping up the distribution of blood and the oxygen content of the patient's body. Experiences on substituting cardiopulmonary bypass with extracorporeal membrane oxygenation in lung transplantation operations have been recorded. The arterial system is a part of the circulatory system. Veno-venous and Veno-arterial extracorporeal membrane oxygenation (ECMO) therapy is utilized to back the cardiac and pulmonary systems in the context of acute failure. The heightening count of hospitals providing ECMO services and the increasing figure of awareness programs are set to propel the growth of the Extracorporeal Membrane Oxygenation (ECMO) Systems Market during the forecast period 2021-2026. This represents the Extracorporeal Membrane Oxygenation (ECMO) Systems Industry Outlook.

Report Coverage

The report: “Extracorporeal Membrane Oxygenation (ECMO) Systems Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Extracorporeal Membrane Oxygenation (ECMO) Systems Market.

By Product Type: Pumps, Oxygenators, Controllers, Cannula, Accessories.
By Modality: Veno-Arterial (VA), Veno-Venous (VV), Arterio-Venous.
By Application: Respiratory Applications, Cardiac Applications, Extracorporeal Cardiopulmonary Resuscitation (ECPR).
By Geography: North America (U.S, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Rest of South America) and Rest Of The World (Middle East, Africa).

Key Takeaways

  • Geographically, North America Extracorporeal Membrane Oxygenation (ECMO) Systems Market accounted for the highest revenue share in 2020 and it is poised to dominate the market over the period 2021-2026 owing to the existence of leading players like Comprehensive Care Services and the boost in the count of innovative product launches in extracorporeal life support (ECLS) in the North American region.
  • Extracorporeal Membrane Oxygenation (ECMO) Systems Market growth is being driven by the backing of the government for valued healthcare and the soaring high buying power balance. However, the complexities related to extracorporeal membrane oxygenation systems or extracorporeal life support (ECLS) like bleeding, infections, and technical failures are some of the major factors hampering the growth of the Extracorporeal Membrane Oxygenation (ECMO) Systems Market. 
  • Extracorporeal Membrane Oxygenation (ECMO) Systems Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Extracorporeal Membrane Oxygenation (ECMO) Systems Market report

Extracorporeal Membrane Oxygenation (ECMO) Systems Market Share, by Region, 2020 (%)


For more details on this report - Request for Sample

Extracorporeal Membrane Oxygenation (ECMO) Systems Market Segment Analysis – By Modality

The Extracorporeal Membrane Oxygenation (ECMO) Systems Market based on modality can be further segmented into Veno-Arterial (VA), Veno-Venous (VV), Arterio-Venous. The Veno Arterial Segment held the largest market share in 2020. This growth is owing to its high application in treating patients with cardiac infarction and helping with algorithm life support plans of action to bring back blood circulation. The benefit of VA-ECMO is that it offers strong biventricular, as against univentricular backing. VA-ECMO is most often utilized in cases of shock with chiefly cardiogenic or obstructive physiology, and less frequently for distributive shock. At the time of the Veno-Arterial (VA) - Extracorporeal Life Support (ECLS), oxygen may also be included in the blood-to-back lung operation if required. Furthermore, the Veno-Venous segment is estimated to grow with the fastest CAGR of 5.7% during the forecast period 2021-2026 owing to the growing occurrences of chronic obstructive pulmonary disease (COPD). The basic operation of the Veno-venous ECMO (VV ECMO) circuit is to facilitate the technique of swap of oxygen and carbon dioxide. It is therefore an important application in cases where the backing of lungs is required.

Extracorporeal Membrane Oxygenation (ECMO) Systems Market Segment Analysis – By Application

The Extracorporeal Membrane Oxygenation (ECMO) Systems Market based on the application can be further segmented into Respiratory Applications, Cardiac Applications, Extracorporeal Cardiopulmonary Resuscitation (ECPR). The Respiratory Applications Segment held the largest market share in 2020. This growth is owing to a boost in the count of patients with respiratory ailments like asthma. As per the World Health Organization (WHO), approximately 262 million people were influenced in 2019 by asthma and 461000 lives were lost. The application of extracorporeal life support (ECLS) has been recorded in the handling of very few patients with almost lethal asthma who continue to display a deep degree of instability despite maximal therapy. Furthermore, the Cardiac Applications segment is estimated to grow with the fastest CAGR of 5.9% during the forecast period 2021-2026 owing to the ability of extracorporeal life support (ECLS) (typically termed Veno-arterial extracorporeal membrane oxygenation, VA-ECMO) to permit cardiocirculatory help and blood decarboxylation and oxygenation in patients with cardiac or cardiorespiratory collapse.

Extracorporeal Membrane Oxygenation (ECMO) Systems Market Segment Analysis – By Geography

The Extracorporeal Membrane Oxygenation (ECMO) Systems Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America (Extracorporeal Membrane Oxygenation (ECMO) Systems Market) held the largest share with 35% of the overall market in 2020. The growth of this region is owing to the increasing predominance of incessant obstructive pulmonary ailments and the existence of advanced healthcare amenities and supportive reimbursement policies which has led to heightened hospital admission rates, which is estimated to increase the operation rates in the region. The survival rates of mature grown-ups with serious acute respiratory failure treated with ECMO have effectively enhanced over the past three decades. As per the Centers For Disease Control And Prevention (CDC), Chronic Obstructive Pulmonary Disease (COPD) makes respiration hard for the 16 million Americans who have this ailment. Furthermore, information from CDC indicates that heaps of people endure COPD, but have not been diagnosed and are not being medically cared for and though there is no cure for COPD, it may be treated. ECMO has been regarded as an effective treatment option for COPD. Furthermore, the Asia-Pacific region is estimated to be the region with the fastest growth over the forecast period 2021-2026. This growth is owing to factors like a boost in spending on healthcare by the government and private firms to enhance healthcare amenities, the increasing populace of the elderly, and the heightening count of patients with respiratory ailments in the heavily-populated countries like India and China which are fuelling the progress of the Extracorporeal Membrane Oxygenation (ECMO) Systems Market in the Asia-Pacific region. 

Extracorporeal Membrane Oxygenation (ECMO) Systems Market Drivers

Increasing Occurrences Of Cardiopulmonary Ailments And Respiratory Failure Is Projected To Drive The Growth Of Extracorporeal Membrane Oxygenation (ECMO) Systems Market

As per the Centers For Disease Control And Prevention, Hantavirus cardiopulmonary syndrome (HCPS) is a serious respiratory disease brought about by the Sin Nombre virus in North America (SNV). As of January 1, 2020, SNV has created 143 laboratory-confirmed cases of HCPS in Canada. Extracorporeal membrane oxygenation support enhances survival of patients with Hantavirus cardiopulmonary syndrome refractory to medical treatment. Respiratory failure is a condition in which the blood does not possess sufficient oxygen or has too much carbon dioxide. Sometimes both the issues can be observed. There is a boost in Extracorporeal life support (ECLS) for acute respiratory failure owing to technological advancements and hopeful results from current investigations in comparison with trials recorded as occurred. ECMO has been utilized as short-term rescue therapy in patients with acute respiratory distress syndrome (ARDS) brought about by COVID-19 and refractory hypoxemia. These determinants are fuelling the growth of the Extracorporeal Membrane Oxygenation (ECMO) Systems Market during the forecast period 2021-2026.

Technological Advancements Are Expected To Boost The Demand Of Extracorporeal Membrane Oxygenation (ECMO) Systems

Technological advancements are driving the growth of the Extracorporeal Membrane Oxygenation (ECMO) Systems market. Extracorporeal membrane oxygenation (ECMO) or Extracorporeal life support (ECLS) has been an essential instrument in the handling of serious cardiorespiratory dysfunction across all age groups of patients for over thirty years. As of 2015, over 78,000 cases have been disclosed to the Extracorporeal Life Support Organization, and the count of centers reporting to this international database, presently over 300 worldwide, has constantly risen. The extracorporeal swap of oxygen and carbon dioxide happens by easy diffusion within an artificial lung or membrane oxygenator, which includes bundles of artificial capillaries or hollow fibers that act as channels for blood, gas, and water. Breakthroughs in hollow-fiber membrane engineering and design are inclusive of the application of fibers designed with PMP, a polymer that has an asymmetric pore structure and outer skin which allows gas permeability but restricts plasma leakage. The Quadrox-iD (Maquet, Rastatt, Germany) was the earliest recognized plasma-tight membrane oxygenator accessible in the U.S., and it was rapidly adopted by ECMO centers. These breakthroughs are driving the growth of the Extracorporeal Membrane Oxygenation (ECMO) Systems market during the forecast period 2021-2026.

Extracorporeal Membrane Oxygenation (ECMO) Systems Market Challenges

Risks of ECMO Are Challenging The Growth Of The Extracorporeal Membrane Oxygenation (ECMO) Systems Market

The application of ECMO or extracorporeal life support (ECLS) has seen an extreme boost in almost all spheres in the U.S. from 2008 to 2014. There are different risks and complexities associated with the application of ECMO. The principal hazard at the time of ECMO treatment is bleeding. When blood is eliminated from the body and siphoned by way of plastic tubing it attempts to clot. To avert this, a blood-thinning drug termed Heparin is utilized. Unfortunately, this may lead to bleeding. Though bleeding may happen in any portion of the body, it is most severe when it happens in the brain and frequently leads to fatal results. The hazard of bleeding is heightened if a surgical operation is needed as part of the treatment while on ECMO. It is also probable that any portion of the ECMO circuit may collapse or break open. Tiny blood clots or air bubbles may potentially infiltrate into the bloodstream of the ECMO circuit. These issues are hampering the growth of the Extracorporeal Membrane Oxygenation (ECMO) Systems Market.

Extracorporeal Membrane Oxygenation (ECMO) Systems Market Landscape:

Novel Product launches, mergers and acquisitions, collaborations, joint ventures, and partnerships are key strategies adopted by players in the Extracorporeal Membrane Oxygenation (ECMO) Systems Market. Key companies of this market include:

  1. Getinge AB
  2. LivaNova PLC
  3. Medtronic
  4. Eurosets S.R.L
  5. Terumo Medical Corporation
  6. Nipro Corporation
  7. Origen Biomedical, Inc.
  8. Medos Medizintechnik
  9. MicroPort Scientific Corporation
  10. Xenios AG (Acquired By Fresenius Medical Care AG & Co. KGaA)

Acquisitions/Product Launches

  • In March 2021, Getinge introduced a novel, complete system for the development of bioreactors. At a time when plenty of medical research spotlight is committed to vaccines, Getinge kicked off a novel, holistic system technique for the development of multi-use bioreactors from Applikon, which was acquired by the Swedish MedTech company in 2020.
  • In July 2020, LivaNova introduced Perceval Plus Valve in Europe. The London-based company has put in place a PMA supplement to FDA for the appliance and it is awaiting review. Perceval Plus is a sutureless surgical aortic valve.

Related Reports:-

Extracorporeal Membrane Oxygenation Machine Market
Report Code: HCR 94088

Global Veno-Venous Ecmo System Industry Market
Report Code: HCR 13305

For more Lifesciences and Healthcare related reports, please click here

1. Extracorporeal Membrane Oxygenation (ECMO) Systems Market - Overview
    1.1 Definitions and Scope
2. Extracorporeal Membrane Oxygenation (ECMO) Systems Market - Executive Summary
    2.1 Market Revenue, Market Size, and Key Trends
    2.2 Key trends by Product Type
    2.3 Key trends by Modality
    2.4 Key trends by Geography
3. Extracorporeal Membrane Oxygenation (ECMO) Systems Market - Comparative Analysis
    3.1 Company Benchmarking – Key Companies
    3.2 Financial Analysis– Key Companies
    3.3 Market Share Analysis– Key Companies
    3.4 Patent Analysis
    3.5 Pricing Analysis- Average Selling Price
4. Extracorporeal Membrane Oxygenation (ECMO) Systems Market - Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Extracorporeal Membrane Oxygenation (ECMO) Systems Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing Business Index
    5.3 Case Studies of Successful Ventures
6. Extracorporeal Membrane Oxygenation (ECMO) Systems Market - Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters Five Force Model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Extracorporeal Membrane Oxygenation (ECMO) Systems Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Extracorporeal Membrane Oxygenation (ECMO) Systems Market – By Product Type (Market Size –$Million/$Billion)
    8.1 Pumps
    8.2 Oxygenators
    8.3 Controllers
    8.4 Cannula
    8.5 Accessories
9. Extracorporeal Membrane Oxygenation (ECMO) Systems Market – By Modality (Market Size –$Million/$Billion)
    9.1 Veno-Arterial (VA)
    9.2 Veno-Venous (VV)
    9.3 Arterio-Venous
10. Extracorporeal Membrane Oxygenation (ECMO) Systems Market – By Application (Market Size –$Million/$Billion)
    10.1Respiratory Applications
    10.2 Cardiac Applications
    10.3 Extracorporeal Cardiopulmonary Resuscitation (ECPR)
11. Extracorporeal Membrane Oxygenation (ECMO) Systems Market - By Geography (Market Size –$Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 U.K.
        11.2.2 Germany
        11.2.3 France
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Russia
        11.2.7 Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of Asia-Pacific
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Rest of South America
    11.5 Rest of the World
        11.5.1 Middle East
        11.5.2 Africa
12. Extracorporeal Membrane Oxygenation (ECMO) Systems Market - Entropy
13. Extracorporeal Membrane Oxygenation (ECMO) Systems Market – Industry/Segment Competition Landscape Premium 
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Competition Matrix
        13.1.5 Best Practices for Companies
14. Extracorporeal Membrane Oxygenation (ECMO) Systems Market – Key Company List by Country Premium Premium
15. Extracorporeal Membrane Oxygenation (ECMO) Systems Market Company Analysis
    15.1Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.